Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Impact of Co-infections on Inflammation in Patients Commencing Second-line Antiretroviral Therapy. A Sub-study of D²EFT (Dolutegravir and Darunavir Evaluation in Adults Failing Therapy)

NCT04183738 is registered in ClinicalTrials.gov with Kirby Institute as lead sponsor.

NCT NCT04183738
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04183738 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Impact of Co-infections on Inflammation in Patients Commencing Second-line Antiretroviral Therapy. A Sub-study of D²EFT (Dolutegravir and Darunavir Evaluation in Adults Failing Therapy)
Lead sponsor
Kirby Institute
Phase
Phase 4
Overall status
Withdrawn
Start date
February 1, 2021
Completion date
December 19, 2022
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cytomegalovirus infections, hiv-infection/aids, human herpesvirus 4 infections, human herpesvirus 8 infection, human papilloma virus